Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70131 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Catherine Thieblemont und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hôpital Saint Louis, Service d'hématologie-Oncologie, Université de Paris Assistance Publique Des Hôpitaux de Paris (APHP), Paris, France. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Cost-Effectiveness Analysis, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bristol Myers Squibb, Bristol-Myers Squibb Canada.
Abstract (Originalsprache)
Objectives
CAR‐T cell therapies such as lisocabtagene maraleucel (liso‐cel) have transformed the treatment of patients with second line primary refractory or early relapsed ≤ 12 months (R/R) large B‐cell lymphoma (LBCL). The objective of this study was to assess the cost‐effectiveness of liso‐cel compared to standard of care (SOC) to treat R/R LBCL in France.
Methods
A 3‐health‐state model was developed to compare liso‐cel to SOC over 20 years in France. Efficacy and safety were extrapolated from the TRANSFORM trial (NCT03575351), or DESCAR‐T (registry of patients treated with a CAR‐T in France). Costs were calculated using French‐specific sources. Outcomes were quality‐adjusted life years (QALY), life‐years (LY), total costs, incremental cost‐utility and cost‐effectiveness ratios (ICUR, ICER). Probabilistic sensitivity analysis (PSA) was conducted to assess the robustness of the results.
Results
Liso‐cel generated 5.7 QALY (6.4 LY) for a €265 907. SOC generated 4.4 QALY (5.1 LY) for €233 903. ICUR and ICER were estimated at €24 580/QALY and €23 464/LY gained versus SOC. PSA showed that liso‐cel was more effective and more costly in 92% of the simulations.
Conclusions
Liso‐cel is cost‐effective versus SOC to treat R/R LBCL patients in France. Generation of long‐term real‐world data is needed in order to validate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hôpital Saint Louis, Service d'hématologie-Oncologie, Université de Paris Assistance Publique Des Hôpitaux de Paris (APHP), Paris, France.
- Bristol Myers Squibb, Health Economics and Outcomes Research Department, Rueil-Malmaison, France.
- Putnam, HTA Operations Department, Paris, France.
- Bristol Myers Squibb, Medial Affairs Department, Rueil-Malmaison, France.
- ESSEC Business School, Cergy, France.
ORCID-Profile: Catherine Thieblemont, Florian Colrat, Marine Sivignon, Sébastien Branchoux, Gérard de Pouvourville
Förderung
- Bristol Myers Squibb
- Bristol-Myers Squibb Canada
Zitieren
APA
Thieblemont, C., Colrat, F., Sellami, R., Sivignon, M., Petel, A., Branchoux, S., & de Pouvourville, G. (2026). Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma. European Journal of Haematology. https://doi.org/10.1111/ejh.70131
Vancouver
Thieblemont C, Colrat F, Sellami R, Sivignon M, Petel A, Branchoux S, et al. Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma. European Journal of Haematology. 2026. doi:10.1111/ejh.70131
BibTeX
@article{Thieblemont2026,
author = {Thieblemont, Catherine and Colrat, Florian and Sellami, Rahma and Sivignon, Marine and Petel, Adrien and Branchoux, Sébastien and de Pouvourville, Gérard},
title = {Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70131}
}
EUVIMED